AstraZeneca buys most of Acerta for $4 billion to add cancer drug: Reuters

AstraZeneca is to buy 55 percent of privately held biotech firm Acerta Pharma for $4 billion to give it access to a new kind of blood cancer drug, boosting its long-term growth at the cost of a near-term hit to earnings, Reuters News reported.

DealsNorth AmericaUSBriefs